Skip to content
etf.net

Launched

iShares Health Innovation Active ETF

BMEDNYSE ArcaC

$33.90−0.35 (−1.04%)

As of Oct 13, 2026, 3:59 PM

C42/ 100

Rank 22 of 35 in US Active Sector

C42/100Rank 22 of 35inUS Active Sector
Intraday session: down, 30 prints from 34.25 to 33.90. Range 33.90 to 34.26. Use the arrow keys to read each point.34.0034.1034.2010 AM12 PM2 PM4 PM
Expense ratio
0.77%
Fund size
$14M
1Y total return
+25.5%
Yield · Last 12 months
0.24%
Holdings
59
Avg volume · 30D
0M sh
NAV per share
$34.27
52W range
low $27.25high $34.98
Launched

The ETF.net BMED Grade

C

Score 42 out of 100

Category
US Active Sector⁠
Rank
22 of 35
Six-pillar profile for BMED. Scores out of 100: Cost 32, Risk 57, Mission 73, Tradability 19, Holdings 79, Durability 59. Strongest: Holdings (79). Weakest: Tradability (19). Leans toward Holdings and Mission.

Score 42 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    D32 out of 100
    Rank 24 of 35

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    A73 out of 100
    Rank 5 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B57 out of 100
    Rank 10 of 35

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F19 out of 100
    Rank 33 of 35

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A79 out of 100
    Rank 6 of 35

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B59 out of 100
    Rank 14 of 35

Our read on BMED

ETF.net Research

CBlackRock's stock-picking take on healthcare's next act: roughly 60 innovative and emerging health companies, actively run rather than indexed. A niche sleeve, priced and traded like one.

Stated mandate

The Fund seeks to maximize total return through active investment in innovative and emerging healthcare companies.

Why people hold it

  1. 01Genuinely active, not an index in disguise: a concentrated book of about 60 names, picked under a mandate to seek total return from innovative and emerging healthcare companies.ishares.com
  2. 02The portfolio holds closely to its stated lane, staying in health innovation rather than drifting toward generic large-cap exposure.
  3. 03Trading since 2020, so there is a multi-year live record from the manager to judge, not a backtest.

Worth knowing

  1. 01At 0.77% a year, it costs more than the typical active US equity fund (median 0.65%). That is the price tag on a specialist stock-picking mandate.
  2. 02Small and thinly traded, so bid-ask spreads run wider and order books thinner than the household-name healthcare ETFs.
  3. 03This is a narrow sector sleeve, not broad-market exposure. Diversified active peers like DFAU (0.12%) and FELC (0.18%) cover the whole US market for a fraction of the fee.

BMED Holdings

As of Oct 12, 2026
Asset class
Stocks
Holdings
59
Top-10 weight
46%
Largest holding
MRNA5.7%

Sectors

  • Health Care100.0%

Geography

  • United States85.56%
  • Switzerland6.01%
  • Denmark2.11%
  • Netherlands1.99%
  • China1.65%
  • United Kingdom1.42%
  • Belgium0.65%
  • Ireland0.62%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001MRNAModerna5.70%3,476$782K286
002GILDGilead Sciences5.54%5,033$761K492
003—Blk Csh Fnd Treasury Sl Agency5.39%740,000$740K437
004DHRDanaher5.18%3,232$710K331
005ABBVAbbVie4.90%2,431$672K522
006TMOThermo Fisher Scientific Inc4.32%902$594K375
007JNJJohnson & Johnson4.14%2,172$568K528
008IQVIqvia Holdings Inc3.64%1,923$500K289
009WATWaters Corp3.63%1,150$499K282
010BIIBBiogen3.54%2,150$485K324
011MTDMettler Toledo3.43%304$471K273
012VRTXVertex Pharmaceuticals3.28%884$451K422
013MRKMerck & Co Inc3.12%2,943$429K515
014EWEdwards Lifesciences2.94%4,736$404K325
015ROP.SWRoche Ps Par AG2.67%853$367K199

Showing 1–15 of 59 holdings

BMED Performance

Launched Sep 29, 2020

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
BMED$12,546
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. BMED $12,546. SPY $12,044. Use the arrow keys to read each point.$9,525$11,271$13,017Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BMED. Periods over one year show the average yearly return.
PeriodBMED
Year to date+13.4%
1 month+4.0%
3 months+11.4%
1 year+25.5%
3 yearsper year+15.9%
5 yearsper year+3.7%
10 yearsFund is under 10 years oldper year—

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BMED
YearReturn barBMED
2026 YTD+13.4%
2025+21.8%
2024+1.6%
2023+5.7%
2022−19.7%
2021−4.0%
2020+19.0%

History from Oct 2, 2020

BMED in the news

Filtered to BMED · US Active Sector

BMED Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
0.24%Last 12 months
Payout per share
$0.08Last 12 months
Last payment
$0.08 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2023–2026

One bar per payment. 2 payments from 2023 to 2026 YTD. Dec 20, 2023 $0.0072; Jun 15, 2026 $0.08. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Jun 15, 2026Jun 18, 2026$0.08
Dec 20, 2023Dec 27, 2023$0.0072

BMED Risk

How much the fund’s monthly returns vary, scaled to a year.
16.0%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.70
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−32.1%
Trough Sep 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.74
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

BMED Cost

Expense ratio0.77%
  • The middle half of US Active Sector funds
  • Median 0.65%

23 of the 35 US Active Sector funds charge less.

BMED costs $77.00 a year on $10,000. The median US Active Sector fund costs $65.00.

Other funds in US Active Sector

See others